Abstract:Currently there is no reliable nomogram to predict the probabilities of having indications for adjuvant prostate radiation therapy for patients with clinically localized prostate cancer who plans radical prostatectomy (RP). The purpose of this study is to examine our cohort of RP patients and to develop the above nomogram through the correlation of pretreatment PSA, clinical T stage and biopsy Gleason Score with adverse features such as extraprostatic extension, positive margin(s), and Gleason Score 8-10 that are commonly indicated for adjuvant radiation therapy. We analyzed 1440 RP patients between August, 2000 and August, 2015 at our hospital. Patients who had a history of neoadjuvant hormonal therapy, or transurethral resection of the prostate (TURP) were excluded from this analysis. A total of 627 patients were eligible for analysis. Average age was 66 years. All patients had a preoperative PSA level, biopsy Gleason Score, pelvic MRI and clinical T stage (TNM 2009 classification). Preoperative PSA level clinical T stage (T2a/b, T2c, T3a, T3b), and biopsy Gleason score (5 to 6, 3+4 = 7, 4 + 3 = 7, 8 to 10) were recorded as preoperative predictors. These predictors were used in multivariable logistic regression analysis based nomograms to estimate the probabilities of extraprostatic extension, positive margin(s), Gleason Score 8-10 after RP, respectively. The predictive accuracy and discriminative ability of the nomogram were determined by concordance index (C-index) and calibration curve. Analyses were performed with open-source statistical software (version 3.2.1). Preoperatively, 41% of patients had a PSA level between 10 and 20 ng/mL, 80% had T2, and 50% had biopsy Gleason score 7; postoperatively, 47% had extraprostatic extension disease, 36% had positive margin, and 22% had Gleason Score 8-10. Nomograms were developed for the predicted probabilities of having the indications of adjuvant radiation therapy (pathologically extraprostatic extension disease or positive margin(s), or Gleason Score 8-10, respectively). The calibration curve for probabilities showed good agreement between prediction by nomogram and actual observation. The C-index of the nomograms for predicting for extraprostatic extension disease, or positive margin(s), or Gleason Score 8-10 were 0.707, 0.659, 0.897, respectively. The risk of having one of the indications of adjuvant radiation therapy increased with increases in predictors except for clinical T stage for predicting Gleason Score 8-10 (P = 0.25). Using clinic-pathological information, we produced nomograms which may accurately predict the probabilities of having indications for adjuvant radiation therapy after RP. This nomogram may help individualize initial treatment options.

The Prognostic Nomogram for PSA-incongruent Low-Risk Prostate Cancer Treated by Radical Prostatectomy

The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy

Survival Analysis and a Novel Nomogram Model for Progression-Free Survival in Patients with Prostate Cancer

A Reliable Nomogram is Identified to Predict the Probabilities of Having Indications for Adjuvant Prostatic Radiation Therapy

The Potential of a Nomogram Combined PI-RADS V2.1 and Contrast-Enhanced Ultrasound (CEUS) to Reduce Unnecessary Biopsies in Prostate Cancer Diagnostics

Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naive patients with PSA PI-RADS v2.1=3 lesions

Nomograms for Predicting Gleason Upgrading in a Contemporary Chinese Cohort Receiving Radical Prostatectomy after Extended Prostate Biopsy: Development and Internal Validation

Diagnostic Performance of a Nomogram Incorporating Cribriform Morphology for the Prediction of Adverse Pathology in Prostate Cancer at Radical Prostatectomy

Establishment and Evaluation of Nomogram for Predicting Biochemical Recurrence in Patients with Locally Adverse Pathologic Features after Radical Prostatectomy

Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with <scp>PSA</scp> <10 ng/ml and <scp>PI‐RADS</scp> v2.1 = 3 lesions

Nomogram Predicting Survival to Assist Decision-Making of Radical Prostatectomy in Patients with Metastatic Prostate Cancer.

Building a Nomogram for Prediction of Prostate Cancer in Patients with Preoperatively Suspected Prostate Cancer

Analysis of the Performance and Accuracy of a PSA and PSA Ratio-Based Nomogram to Predict the Probability of Prostate Cancer in a Cohort of Patients with PIRADS 3 Findings at Multiparametric Magnetic Resonance Imaging

A Novel Nomogram Combined PIRADS V2 and Neutrophil-to-lymphocyte Ratio to Predict the Risk of Clinically Significant Prostate Cancer in Men with PSA < 10 Ng/ml at First Biopsy

Can a nomogram predict apical prostate cancer pathology upgrade from fusion biopsy to final pathology? A multicenter study

The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b

Nomogram for predicting the overall survival of patients with early-onset prostate cancer: A population-based retrospective study

Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data

Development and Validation of a Nomogram for Predicting the Overall Survival of Prostate Cancer Patients: a Large Population-Based Cohort Study.

Integration of Multiparameter MRI into Conventional Pretreatment Risk Factors to Predict Positive Surgical Margins after Radical Prostatectomy.